Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Tumor Immunotherapy01:27

Tumor Immunotherapy

596
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
596
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

7.7K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.7K
Cytotoxic T Cells-mediated Immune Response01:27

Cytotoxic T Cells-mediated Immune Response

1.0K
Cytotoxic T cells are a vital component of the immune system. They have the remarkable ability to identify and target antigens on infected or abnormal cells. These antigens often originate from intracellular pathogens such as viruses or abnormal proteins cancer cells produce.
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
1.0K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

5.0K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.0K
Cancer Vaccines01:30

Cancer Vaccines

456
Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
456

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Addition of Metastasis-Directed Therapy to Standard of Care for Oligometastatic Disease: Primary Aggregated Analysis of All Baskets from the Phase II Randomized EXTEND Trial.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026
Same author

Nivolumab plus ipilimumab for chemotherapy-refractory metastatic castration-resistant prostate cancer: results from the randomized portion of the phase 2 CheckMate 650 trial.

Nature communications·2026
Same author

Prevalence of adverse events following T-cell redirecting therapies in patients with metastatic castration-resistant prostate cancer: a pooled analysis.

The oncologist·2026
Same author

Fangchinoline derivative LYY-34 suppresses TNBC by inhibiting BLM DNA helicase from unfolding of c-MYC promoter G-quadruplex DNA.

Biochemical pharmacology·2026
Same author

Correction: Navigating drug-drug interactions with apalutamide.

Prostate cancer and prostatic diseases·2026
Same author

The path forward for T cell engagers in patients with prostate cancer.

Journal for immunotherapy of cancer·2026

相关实验视频

Updated: Aug 2, 2025

An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis
06:38

An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis

Published on: September 12, 2019

8.9K

免疫检查点治疗 - 目前的前景和未来的方向

Padmanee Sharma1, Sangeeta Goswami2, Deblina Raychaudhuri3

  • 1Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA; Department of Immunology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA; The Immunotherapy Platform, The University of Texas MD Anderson Cancer Center, Houston, TX, USA; James P. Allison Institute, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

Cell
|April 14, 2023
PubMed
概括

免疫检查点治疗 (ICT) 提供持久的癌症益处,但反应率有所变化. 了解免疫和非免疫因素对于优化患者选择和提高ICT有效性至关重要.

关键词:
在 CTLA-4信息和通信技术美国其他类型组合生物标志物细胞毒性T淋巴细胞相关蛋白4免疫检查点治疗与免疫相关的不良事件其他编程细胞死亡蛋白1编程死亡连接体1反向翻译

更多相关视频

Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells
09:04

Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells

Published on: March 7, 2025

511
Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology
07:04

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology

Published on: May 2, 2025

462

相关实验视频

Last Updated: Aug 2, 2025

An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis
06:38

An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis

Published on: September 12, 2019

8.9K
Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells
09:04

Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells

Published on: March 7, 2025

511
Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology
07:04

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology

Published on: May 2, 2025

462

科学领域:

  • 免疫学
  • 癌症学
  • 癌症治疗

背景情况:

  • 免疫检查点疗法 (ICT) 彻底改变了癌症治疗,
  • 不同瘤类型的ICT反应率的变化需要更好的患者选择策略.
  • 识别预测生物标志物对于最大限度地提高ICT的有效性和最大限度地减少与治疗相关的毒性至关重要.

研究的目的:

  • 审查影响对ICT反应和耐药性的抗瘤免疫的生物机制.
  • 讨论当前面临的挑战和持续努力,以提高ICT的有效性.
  • 概述未来临床试验和涉及ICT的组合疗法的策略.

主要方法:

  • 专注于抗瘤免疫力的文献综述.
  • 对免疫检查点抑制剂影响反应和耐药性的分析.
  • 综合数据以指导未来的临床发展.

主要成果:

  • 详细探讨影响ICT结果的免疫和非免疫因素.
  • 确定阻碍更广泛的ICT应用的主要挑战.
  • 建议优化患者选择和组合治疗的策略.

结论:

  • 对抗瘤免疫的全面了解对于推进ICT至关重要.
  • 解决目前的局限性需要多方面的方法,包括生物标志物的发现.
  • 未来的研究应该集中在组合策略和精细的临床试验设计上,以增强ICT的好处.